3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
80
Breast Neoplasms
39
Neoplasms
6
Neoplasm Metastasis
4
Leiomyoma
2
Infertility
2
Breast Neoplasms, Male
2
Stage I Prostate Adenocarcinoma AJCC v7
1
Sexual Dysfunction, Physiological
1
Sarcopenia
1
Salivary Gland Neoplasms
1
Recurrence
1
Primary Dysautonomias
1
Patient Compliance
1
Ovarian Neoplasms
1
Osteoporosis
1
Osteitis Deformans
1
Lymphatic Metastasis
1
Kidney Diseases
1
Hypertension
1
Hyperlipidemias
1
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
1
Hodgkin Disease
1
Hereditary Sensory and Autonomic Neuropathies
1
Hemorrhage
1
Fallopian Tube Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Ovarian Epithelial
1
Bulbo-Spinal Atrophy, X-Linked
1
Advanced Prostate Cancer
1
Interventions
Everolimus
5
Alpelisib
4
berzosertib
3
PX-866
3
Letrozole
3
Fulvestrant
3
Cetuximab
3
Topotecan
2
NVP-BKM120
2
tipifarnib
1
sotorasib
1
serabelisib
1
ribociclib
1
pembrolizumab
1
parsaclisib
1
palbociclib
1
gedatolisib
1
duvelisib
1
ceralasertib
1
capivasertib
1
binimetinib
1
Trimetazidine
1
Paclitaxel
1
Oxaliplatin
1
Leuprolide
1
Leucovorin
1
Irinotecan
1
Goserelin
1
Fluorouracil
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hereditary Sensory and Autonomic Neuropathies
×
Goserelin
×
Clear all
NCT03056755
2026-01-13
BYLieve
Novartis
Phase 2
Completed
383 enrolled
16 charts